Curcumin as a potential treatment for COVID-19
Nenhuma Miniatura disponível
Data
2021
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Coronavirus disease 2019 (COVID-19) is an infectious disease that rapidly spread
throughout the world leading to high mortality rates. Despite the knowledge of
previous diseases caused by viruses of the same family, such as MERS and SARS CoV, management and treatment of patients with COVID-19 is a challenge. One of the best
strategies around the world to help combat the COVID-19 has been directed to drug
repositioning; however, these drugs are not specific to this new virus. Additionally, the
pathophysiology of COVID-19 is highly heterogeneous, and the way of SARS-CoV-2
modulates the different systems in the host remains unidentified, despite recent
discoveries. This complex and multifactorial response requires a comprehensive
therapeutic approach, enabling the integration and refinement of therapeutic responses
of a given single compound that has several action potentials. In this context, natural
compounds, such as Curcumin, have shown beneficial effects on the progression of
inflammatory diseases due to its numerous action mechanisms: antiviral, anti inflammatory, anticoagulant, antiplatelet, and cytoprotective. These and many other
effects of curcumin make it a promising target in the adjuvant treatment of COVID-19.
Hence, the purpose of this review is to specifically point out how curcumin could interfere at
different times/points during the infection caused by SARS-CoV-2, providing a substantial
contribution of curcumin as a new adjuvant therapy for the treatment of COVID-19.
Descrição
Palavras-chave
Curcumin, COVID-19, SARS-CoV-2, New therapies, ACE2
Citação
RATTIS, Bruna A. C.; RAMOS, Simone G.; CELES, Mara R. N. Curcumin as a potential treatment for COVID-19. Frontiers in Pharmacology, Lausanne, v. 12, e675287, 2021. DOI: 10.3389/fphar.2021.675287. Disponível em: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.675287/full. Acesso em: 5 fev. 2025.